A. Adam

Short-Term Neuropsychiatric Tolerability of Bictegravir Combined with Emtricitabine/Tenofovir Alafenamide in Clinical Practice

H. Stellbrink, C. Hoffmann, K. Schewe, 2020, Antiviral therapy.

Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.

G. Wassmer, R. Maserati, L. Weitner, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

Drug-resistant genotyping in HIV-1 therapy

L. Weitner, R. Laufs, B. Zöllner, 1999, The Lancet.

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)

J. van Lunzen, C. Schneider, H. Stellbrink, 2002, AIDS.

CD4-cell counts and presence of AIDS in HIV-positive patients entering specialized care—a comparison of migrant groups in the German ClinSurv HIV Cohort Study, 1999–2013

J. van Lunzen, H. Stellbrink, J. Rockstroh, 2016, BMC Infectious Diseases.

Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients.

L. Weitner, R. Laufs, B. Zöllner, 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

First‐line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48‐week results

P. Gute, J. Rockstroh, B. Salzberger, 2002, HIV medicine.